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Abstract: The pharmacological treatment for stable COPD is based on the use of inhaled 
bronchodilators (long-acting muscarinic receptor antagonists and long-acting beta-2 adreno-
ceptor agonists) and inhaled corticosteroids. The use of triple inhaled therapy is recommended 
to selected patients with COPD. Among the various inhaler combinations in triple therapy, 
a new combination by fluticasone furoate, umeclidinium, and vilanterol is available for COPD 
patients. Recently, a large clinical trial using this combination has been published, resulting in a 
reduction in exacerbation rate in COPD patients. Furthermore, this combination has demonstrated 
efficacy and safety, with a single administration a day, through a dry powder inhalator device, 
which has shown a good adherence and is a preference of the patient. This review focuses on 
the main characteristics of this inhaler combination evaluating the main clinical effects, the 
patients’ adherence, and the safety.
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Introduction
COPD is a common, preventable, and treatable disease characterized by persistent 
respiratory symptoms and airflow limitation due to alveolar and/or airway abnor-
malities, usually caused by significant exposure to harmful particles or gases.1 
COPD represents a major public health problem, being a disease with a prevalence 
of 10% in Europe.2,3 Epidemiological estimates related to this pathological condi-
tion also describe an expanding disease, which in recent decades has become the 
third leading cause of death in the world. The burden of the disease also depends 
on the presence of comorbidity and on the frequency of exacerbations. The latter is 
responsible for 50%–75% of the costs of the disease, especially if the patients then 
require hospitalization.1 Therefore, the attention is increased toward prevention 
campaigns focused on risk factor control, an early diagnosis, and an optimal treat-
ment for both stable disease and exacerbations. In fact, the objectives of drug therapy 
aim at obtaining an optimal control of the current pathology, acting primarily on the 
reduction of symptoms, on the improvement of patients’ performance status, and on 
the control of future risk, through a blockade of functional decline and prevention of 
exacerbations. These goals must be achieved by optimizing the therapy, in order to 
reduce the side effects, maximize the impact of treatment, and improve the compli-
ance to the therapy. The latter represents a critical point in respiratory patients as it is 
approximately at 15%.4 The choice of the device and the methods of administration 
also play a fundamental role.1
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A focal point in the treatment of COPD is represented 
by the patients’ adherence to the treatment,5 which in turn 
depends on the perception of the disease, the safety of the 
therapy, and the reduction of their symptoms. Furthermore, 
an important point for the patients’ adherence to the treatment 
is the ease of use of the device or the number of the devices 
used for the therapy.
Several clinical trials take this into account and include 
methods of measuring patient satisfaction and the impact of 
therapy on quality of life.
This review will focus on the use of triple inhaled therapy 
with a particular focus on the once-a-day dry powder inha-
lator (DPI) fixed-dose combination of fluticasone furoate 
(FF), umeclidinium bromide (UMEC), and vilanterol trife-
natate (VI).
The role of triple inhaled therapy 
in COPD
The inhaled therapy used in COPD consists in heterogeneous 
pharmacological classes that can act on the lungs by different 
mechanisms of action, determining a bronchodilation, and 
therefore the improvement of many functional parameters. 
In this way, they can have important repercussions on the 
patients’ state of health, on their performance status, and on 
the quality of life.6 Moreover, through inhaled administra-
tion, it is possible to reduce the side effects given by systemic 
administration, even if these events cannot be completely 
eliminated. The categories of drugs referred to in this case 
are mainly antimuscarinic agents, beta-2 agonists, and 
corticosteroids.
Antimuscarinic agents act at the pulmonary level mainly 
by antagonizing the acetylcholine binding at the postsynaptic 
level on the M3 receptor and at the presynaptic level on the 
M2 receptor. They directly regulate the bronchial tone at 
the pulmonary level and at the systemic level, act on glands 
and epithelia, regulating the production and the clearance 
of mucus, the frequency of ciliary beating, and in general 
they can carry out a regulatory action on inflammation. The 
differences between the various agents belonging to this 
pharmacological category are related to the action selectivity, 
the time of action, and the speed of action.7
Beta-2 agonists are an important pharmacological cat-
egory for the treatment of bronchoconstriction. They act by 
binding to the beta-2 adrenergic receptor, which ultimately 
determines bronchodilation through the production of cAMP. 
Many molecules for this pharmacological category have been 
developed over the years, with some molecules focused on 
speed and duration of action, while others on selective recep-
tor and, therefore, for efficacy and safety.8 In addition to the 
bronchodilator effect, they may also have other functions at 
the pulmonary level, such as regulation of the inflammatory 
activity and inhibition of cholinergic action. This, therefore, 
is a synergistic effect with respect to antimuscarinic agents 
and a synergistic action also of glucocorticoids action.
Inhaled glucocorticoids (ICS) are the most important 
regulators of the inflammatory state of the airways. The 
mechanisms of action of glucocorticoids are very complex: 
they can regulate through the binding to specific receptors 
in gene transcription of many elements of inflammation, 
suppressing proinflammatory genes, and activating antiin-
flammatory genes instead. In this way, they can reduce the 
numbers of inflammatory cells at cellular level, including 
eosinophils, T-lymphocytes, mast cells, and dendritic cells.9 
These three classes of drugs act among them with synergic 
action by increasing the receptor expression and binding, by 
increasing the antiinflammatory effect, and by modulating 
the mediator release (Figure 1).10,11
According to the GOLD guidelines, the most appropri-
ate therapeutic choice for a COPD patient begins with the 
classification of his/her disease severity. The identifica-
tion of subgroup to which the patient belongs is important 
because these specific recommendations can guide the 
physician to decide whether to start with an inhaled mono-
therapy or eventually move to a combination therapy of long 
acting beta agonist (LABA) and long acting muscarinic 
antagonist (LAMA).
In patients characterized by the most severe functional 
and symptomatic alteration and by the highest risk of exac-
erbations in groups D and C, the use of a triple combination 
LAMA, LABA, and ICS may be recommended.1
The treatment of patients with COPD should be con-
structed based on patients’ spirometric values, symptoms, 
and perception of the patients’ disease, as well as on the 
frequency of exacerbations. Therefore, patients in stage A, 
less symptomatic, with a pathology of lesser severity and with 
less probability of exacerbations, should start the treatment 
with a single bronchodilator. In group B, similar to group A 
in terms of clinical–instrumental features, but with more pro-
nounced symptoms, patients can benefit from a long-acting 
bronchodilator, and in case of persistence of symptoms, from 
the combination of two long-acting bronchodilators.1
In the case of greater flow limitations and greater pos-
sibility of COPD exacerbations, it is possible to introduce 
an inhaled ICS therapy, either in combination with another 
bronchodilator if the patient is not very symptomatic, or in 
triple therapy if the patient is strongly symptomatic.
However, while the central role of bronchodilators in 
COPD is clearly established, controversy exists regarding the 
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use of ICS in COPD.12 In fact, the use of ICS may increase the 
risk of developing respiratory infections such as pneumonia. 
Furthermore, a retrospective general practice cohort study in 
the United Kingdom has shown that the rate of exacerbations 
requiring hospitalizations did not change, notwithstanding 
the increased number of prescriptions for LABA plus ICS 
combinations.13
The identification of patients with an asthmatic compo-
nent or the identification of elevated levels of eosinophils 
could in fact identify a group of patients more sensitive to 
this therapy. However, the use of a triple therapy is recom-
mended only in patients of group C or D, which despite the 
combination therapy of LABA and LAMA still show severe 
symptoms or frequent exacerbations.1
Clinical studies dedicated to the evaluation of the efficacy 
and safety of triple therapy have not reached an absolute 
agreement.
Many clinical studies have shown that the LABA/LAMA/
ICS combination is able to demonstrate a significant improve-
ment in the functional parameters of patients with moderate 
to severe COPD, compared with LAMA alone.14–18 These 
studies have shown an improvement in FEV
1
 and other 
physiological and symptomatological parameters, after the 
transition to triple therapy, such as the values of lung volumes 
or airway conductance, with statistically significant differ-
ences. The same studies did not give consistent data regarding 
exacerbations. In some cases,14,19,20 the exacerbations seemed 
significantly reduced, while in other comparative studies no 
significant differences were observed.16,18,21 These data could 
also be influenced by the criteria for defining and identifying 
the exacerbation, the difference in the inclusion criteria, and 
the duration of the follow-up. The effect on COPD exacerba-
tions was studied on a Scottish cohort by Manoharan et al,22 
which demonstrated a reduction in exacerbations and related 
hospitalizations and a reduction in overall mortality when 
patients are treated with triple therapy or with ICS/LAMA 
combination compared with the ICS combination with LABA 
alone. In a deep analysis of the individual causes of death, 
only the triple therapy was recognized to be able to signifi-
cantly reduce the cardiovascular mortality.22
However, when triple therapy is prescribed in carefully 
selected patients, univocal data emerge: a statistically sig-
nificant improvement in the quality of life, a lower use of 
the drug when needed, and an improvement in symptoms 
of dyspnea and pulmonary function when compared with 
LAMA alone.14–18 Less evidence is available in the literature 
on the comparison of the triple therapy to the therapy with 
LAMA/LABA, often with discordant results. A meta-analysis 
has shown that the combination indacaterol/tiotropium can 
have effects on lung function and quality of life overlap-
ping the triple therapy.23 A comparison study of the inhaled 
triple therapy versus the tiotropium/salmeterol combination 
demonstrates a risk of overlapping exacerbations between 
patients who continue and those who stop ICS, even if in the 
latter a decline in the spirometric parameters is observed in 
the final stages of the study.24
The appropriateness of prescription is another point 
which has to be considered. In fact, the lack of a well-defined 
indication for triple inhaled therapy for COPD results in 
differences in real-life prescription patterns. Accordingly, 
Brusselle et al has shown in the UK, a prescription of triple 
therapy not always in accordance with the recommendations 
listed in the guidelines, observed patients with COPD GOLD 
A and B in treatment with triple therapy.25 Di Marco et al 
has shown a poor prescriptive appropriateness even in Italy, 
also highlights a low demand for spirometry and specialist 
examinations by the general practitioner.26 These data are 
not of little importance if we consider that this therapy is not 
without side effects, attributable in particular to the chronic 
use of corticosteroids.25,27–29
Figure 1 Schematic representation of synergic mechanisms of antimuscarinic agents, beta-2 agonists, and inhaled corticosteroids.
Abbreviations: LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist.
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The new combination of FF/
umeclidinium/vilanterol inhaler
Among the various inhaler combinations in triple therapy, 
a new combination is given by FF/UMEC/VI.
FF is a potent corticosteroid with antiinflammatory action 
that acts by preserving epithelial integrity and reducing 
epithelial permeability in response to protease-induced cell 
damage or resulting from mechanical damaging stimuli.18
UMEC acts for competitive antagonism on muscarinic 
receptors. It has a very strong bond with the M3 receptor 
comparable to that of tiotropium, with a speed of dissociation 
from the M3 receptor slower than that from the M2 receptor. 
The time required to reach the maximum concentration is 
between 5 and 15 minutes, ensuring a remarkable speed of 
action. This kinetics results in a long-lasting bronchodilation 
and, therefore, in the possibility of a single daily dose.30
VI is a powerful and selective beta-2 agonist, which was 
developed in combination with FF in the treatment for asthma 
and with UMEC for COPD. It represents a good rapidity 
of action, since after its intake, it reaches its maximum 
concentration after about 10 minutes. It also has a minimal 
systemic absorption and therefore an optimal safety profile. 
VI is metabolized into compounds that continue to have 
an action, resulting in a long duration of action.31 In some 
preclinical models, VI showed a significantly faster action 
of onset versus that of salmeterol and a longer duration of 
action than salmeterol and formoterol.32
The efficacy of the combination between UMEC and 
VI has already been studied after the introduction of dual 
bronchodilation. In fact, many studies have shown the effi-
cacy of this combination33–35 and a good safety profile.33 The 
UMEC/VI combination has shown a positive influence on 
the quality of life of the treated patients.36
Symptoms and functional parameters
The combination of FF/UMEC/VI gave positive results when 
the effects were studied using two separate DPIs.37 The same 
combination of FF/UMEC/VI gave positive results also 
when compared with other ICS + LABA combinations in 
improving lung function and health status, for the first time 
in the FULFIL study, in which the drugs are administered 
only once a day from the same device.38
The FULFIL study was a 24-week, randomized, double-
blind, double-dummy, parallel-group, multicenter study, 
which involved 1,810 patients with moderate or severe 
COPD and with a history of at least two or more moderate 
or one severe exacerbation (requiring hospitalization) in the 
previous 12 months after recruitment. The recruited patients 
also had a significant symptomatology, demonstrated by a 
COPD assessment test (CAT) score of $10 at the entrance 
to the study. The patients were divided into two groups, one 
of which received the triple FF/UMEC/VI therapy and the 
other with budesonide/formoterol. This study showed an 
improvement of FEV
1
 in the first arm compared with the 
ICS + LABA combination. In fact, an increase of 142 mL 
was observed at FEV
1
 at the end of 24 weeks in the study arm 
which included patients who had received the triple therapy, 
compared with a worsening of FEV
1
, of about 29 mL, in those 
who had received the ICS + LABA combination.38
The FULFIL study also showed an improvement in the 
patients’ symptomatology, demonstrated by a reduction of 
6.6 points in the result of the St George respiratory question-
naire (SGRQ) test at the end of the 24 weeks of observation 
in the first arm, and of 4.3 points in the second arm. The 
beneficial effects of triple therapy have also been evident in 
terms of reduced use of the drug when needed.
The advantages shown by the FF/UMEC/VI combina-
tion have also been confirmed by comparing FF/VI with 
UMEC using different devices. Bremner et al has shown, in 
a Phase III, multicenter, randomized, double-blind, parallel-
group study, that the inhalation of the triple therapy with a 
single device is not inferior to the inhalation of the same 
therapy if administered in two different devices.39
An important response to the use of FF/UMEC/VI com-
bination has been given by the IMPACT trial, a 52-week 
Phase III, randomized, double-blind, three-arm, parallel-
group, global multicenter study, which was completed in 
July 2017 and published in April 2018.40
In this study, the primary outcome was to compare the 
rate of moderate and severe exacerbations between single-
inhaler FF/UMEC/VI and single-inhaler FF/VI or UMEC/VI 
in .10,000 patients affected by severe-to-very severe COPD. 
The comparison of single-inhaler triple ICS/LABA/LAMA 
therapy versus single-inhaler dual LAMA/LABA therapy is of 
particular relevance, as the lack of similar studies represents 
an unmet need in pharmacological treatment of COPD.
Patients completed an electronic diary each morning to 
record their symptoms. The severity of an exacerbation was 
defined according to the treatment. The rate of moderate 
or severe exacerbations was significantly lower with the 
combination of FF, UMEC, and VI (0.91 per year) than with 
FF/VI (1.07 per year) or UMEC/VI (1.21 per year).40
For the spirometric outcome of the mean change from 
baseline in trough FEV
1
, the difference between the triple 
therapy and the FF/VI groups was 97 mL (95% CI, 85–109; 
P,0.001), and the difference between the triple therapy 
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and the UMEC/VI groups was 54 mL (95% CI, 39–69; 
P,0.001).
Quality of life
Several clinical trials have been performed to assess the 
patients’ general state of health and disease perception includ-
ing the quality of life (HRQoL)41,42 using various question-
naires. One of the most complete questionnaires is the SGRQ, 
a questionnaire used for both asthma and COPD.43 The SGRQ 
is the tool used to discriminate between patient differences 
and to assess changes in perception in the same patient over 
time. Another questionnaire, the CAT, consists in fact only 
eight questions, whose answer can be easily identified on a 
scale from 1 to 5, the higher the number, the more serious 
the condition of the patient in relation to that disorder.44 This 
test was used in the FULFIL study to evaluate the patients’ 
symptoms at the entrance to the study: being required that 
the patients were symptomatic, one of the inclusion criteria 
provided a CAT score $10.
The FULFIL study demonstrated a statistically signifi-
cant improvement in HRQoL. At the entrance to the study, 
the patients were selected according to CAT. Subsequently, 
the BDI (Basic Dyspnea Index) was administered as an 
interviewer-administered rating of severity of dyspnea at a 
single state. On subsequent visits, the patients’ health status 
was investigated through the SGRQ and the Transition 
Dyspnea Index, which measure changes in dyspnea severity 
from the baseline, as established by the BDI. The patients 
only carried out the CAT again at the final visit. At the end of 
the FULFIL study, an improvement in HRQoL was observed 
in both arms of the study at week 24, but the mean changes 
from baseline in the triple therapy group were statistically 
higher than those in the dual therapy group, if they evaluated 
the total scores of both the CAT and the SGRQ.45 The SGRQ 
score, in fact, varies by 2.2 points in the group treated with 
triple therapy compared with the group treated with ICS + 
LABA and the CAT score shows a difference of 0.9 points 
in the improvement sense in the first group compared with 
the second at the end of the study.
The FULFIL study also demonstrated a statistically 
significant improvement in the triple therapy group com-
pared with the arm of ICS + LABA in functional limitation 
and a socioeconomic benefit assessed by administering the 
health care resource utilization questionnaire, a tool designed 
to estimate the use of economic resources in the medical 
field, to patients.46
The total cost of patients in triple treatment is greater at 
24 weeks, but it was lower than the second arm if instead 
the observation is prolonged to 52 weeks. These socioeco-
nomic evaluations should be reassessed in light of the fact 
that these findings were made in the FULFIL study only 
in the UK and that the economic benefit was demonstrated 
only at 52 weeks.28
The effect of single-inhaler FF/UMEC/VI versus single-
inhaler FF/VI or UMEC/VI in COPD on changes in SGRQ 
total score has also been a secondary outcome of the IMPACT 
trial.40 In this study, the patients with triple therapy presented 
an improvement in mean change from baseline in the SGRQ 
total score when compared with the FF/VI and UMEC/VI 
groups.
Adherence to the treatment
Medication adherence in patients with COPD, like with all 
chronic disorders, is complex, although it is crucial for the 
best outcomes. Therapeutic adherence can be influenced by 
several factors relating to disease severity, the doctor–patient 
relationship, the socioeconomic factors, and the therapy 
itself. In particular, this includes the frequency of administra-
tion, the speed of action of the drug, and the manageability 
of the device.47–49
It is evident that a simpler therapeutic scheme will guar-
antee a better adherence of the patient, especially in COPD 
patients, which more frequently affect elder patients, often 
suffering from other comorbidities and therefore assuming 
numerous drugs. In these patients, it is suggested to sim-
plify the treatment. Indeed, many studies have shown that 
patients are more compliant with once daily administration 
than treatment regimens twice or three times a day.50,51 In a 
large retrospective study (55,076 COPD patients), medica-
tion adherence strongly correlated with dosing frequency.52 
Furthermore, patients using multiple inhalers experienced 
more exacerbations.53
In COPD patients, the poor adherence to the treatment 
may depend on the difficulty or insufficient training to the 
device.54,55 The choice of the most appropriate device also 
depends on the patient’s clinical condition. The devices cur-
rently in use are varied. In particular, there are metered-dose 
inhaler (MDI) devices on one side and DPI devices on the 
other. The first are spray or MDI aerosols predosed in pres-
surized cans, characterized by a high delivery speed, which 
increases the oropharyngeal deposition and therefore the fre-
quency of local side effects and provide a good coordination 
of the patient to properly perform the inhalation. DPI devices 
are powder dispensers, which do not require coordination by 
the patient, do not contain propellants, and have reproduc-
ibility of the delivered dose. The disadvantage is represented 
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by the need to apply an inhalation effort sufficient to inhale 
the powder from the device and the possibility that it will 
trigger the cough. DPI devices can be monodose or multidose. 
Next to these, soft mist inhaler and ultrasonic or compressed 
air nebulizers can be added. Although some studies have 
shown greater adherence to treatment with MDIs compared 
with DPIs,56 other studies demonstrate greater efficacy of 
administration in DPI devices or an equal effectiveness 
between the two types of devices.
Ramadan and Sarkis have shown that ~70% of patients 
using DPI perform therapy correctly compared with about 
40% of those using MDI.57 In this study, ~81.4% of MDI 
users identify the coordination between container pressure 
and inhalation as the most difficult passage. These results 
are probably explained by the less complex administration 
(no coordination is needed) with DPI. The discrepancy 
between the various studies is an expression that there is no 
ideal inhaler, but we must choose the most appropriate device 
to the characteristics of the patient to be treated and the drug 
to be administered. All the devices present advantages and 
disadvantages. The common errors for both DPI and MDI 
were expiration before the dose, apnea after the dose, waiting 
between two consecutive doses, and finally gargle after a 
dose of corticosteroids.57,58
However, the ideal device should have a low internal 
resistance, allow a good reproducibility of the dose, generate 
a high fraction of fine particles, and, therefore, determine a 
high pulmonary deposition. At the same time, a good device 
should be easy to use, have a system for checking the dose 
inhalation and a simple system for the counting of doses, 
and should be resistant to the action of any external agents, 
such as humidity or trauma.
The ELLIPTA device, which is the tool to administrate 
FF/UMEC/VI, is a device with a dose counting system and 
a medium-low resistance system, which does not dispense 
preestablished suspensions, but determines the mixing of 
the doses of the different drugs at the time of the activation 
of the flow from the patient. It does not have any humidity 
control systems, so there is a deadline after 6 weeks.59,60 
Several studies have demonstrated the efficacy of this device 
(Table 1). Svedsater et al have reported a positive opinion 
with the use of ELLIPTA in patients with asthma and COPD 
already in treatment with other devices. This was due to the 
lowest number of steps to be taken in order to inhale the 
drug, the compactness of the device and the size, the ease 
in remembering the operation, the size of the mouthpiece, 
and other features.61 This was confirmed by van der Palen 
et al62 who showed fewer errors in patients using ELLIPTA 
compared with naive patients who used other devices.
ELLIPTA was compared with both Diskus63 and Han-
dihaler devices.64 In both the studies, the patients expressed 
preference for ELLIPTA regarding the ease of use and 
therefore the characteristics of the device itself. Accordingly, 
Komase et al reported similar results in a Japanese popula-
tion, demonstrating a preference of patients for ELLIPTA in 
particular, for ease of use, number of steps needed, and time 
taken to operate the inhaler.65
Several recent randomized controlled trials evaluated 
the efficacy and safety of triple ICS/LABA/LAMA therapy 
using a single fixed-dose combined inhaler for patients 
with COPD.19,20
Bremner showed that FF/UMEC/VI administered with 
only one inhaler was not inferior to FF/VI plus UMEC 
administered at the same dosages but in two separate devices, 
in terms of improvement of FEV
1
. His findings confirm that 
triple therapy with a single inhaler with FF/UMEC/VI offers 
similar efficacy, health, and quality of life, such as the triple 
therapy administered with two separate inhalers.66
At the final study visit, patients were also asked to 
express a preference regarding the device: among patients 
Table 1 Studies comparing eLLiPTA with other devices
Study Year Number 
of COPD 
patients
Primary endpoint Results
Svedsater et al61 2013 42 Comparison among eLLiPTA and other devices 
about their satisfaction with various attributes of 
the inhalers
The eLLiPTA was associated with high patient 
satisfaction and was preferred to other inhalers when 
participants with asthma and COPD were interviewed
Komase et al65 2014 150 Preference for ease of use between eLLiPTA and 
the Breezhaler device
The eLLiPTA was preferred for ease of use and 
number of steps
van der Palen et al62 2016 567 errors in the use of the eLLiPTA compared to 
other devices
Fewer errors in patients using eLLiPTA in naive 
patients
Yun Kirby et al63 2016 287 inhale preference based on size of the numbers on 
the dose counter
More patients preferred five specific inhaler attributes 
of the eLLiPTA when compared with Diskus
Collison et al64 2018 214 Preference between eLLiPTA and Handihaler based 
on the number of steps needed to use the inhaler
Preference for eLLiPTA
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who expressed a preference, there was a greater preference 
for the ELLIPTA inhaler than the Turbuhaler.45
Safety
Pharmacokinetic studies do not suggest clinically relevant 
pharmacokinetic differences between FF, UMEC, or VI 
intake when given as a triple therapy compared to separate 
FF/VI and UMEC/VI. It can, therefore, be assumed that 
the lung dose and safety of all three agents, delivered by a 
single inhaler, are similar to those of the approved FF/VI and 
UMEC/VI therapies.67
Two randomized trials were conducted to study the safety 
and efficacy of UMEC added to FF/VI.37,67 When the use of 
FF/VI or UMEC was compared with the triple combination 
of UMEC/FF/VI, no major adverse or side effects were 
observed, and the therapy was generally well tolerated. 
In fact, few adverse events were observed, and the experi-
menters did not consider that they were to be attributed to the 
therapy in progress. The most common side effects reported 
include nasopharyngitis, headache, and back pain.38 In both 
studies on this combination, totally, six deaths were reported 
but were not considered to be related to study treatment. Only 
one serious adverse event of diabetes mellitus was reported, 
which was shown to be a previously undiagnosed case of 
type 2 diabetes mellitus.37,67
Conclusion
The inhaler triple therapy with ICS/LAMA/LABA has dem-
onstrated efficacy and safety in clinical studies, obviously 
with a variability based on the endpoint considered. The triple 
therapy has in fact shown efficacy in terms of respiratory 
function and quality of life.
An important point among the considerations regarding 
the triple therapy is the identification of the subgroup of COPD 
patients deserving to be treated with this protocol. Therefore, 
a correct diagnosis and stratification of the disease’s severity 
are needed. In other terms, it is necessary and fundamental 
to identify the group of patients that can best respond to the 
combined treatment with ICS/LAMA/LABA.
Currently, several inhaler combinations in triple therapy 
are being produced. In particular, the FF/UMEC/VI combi-
nation has demonstrated efficacy and safety, with a single 
administration a day, through a DPI device, especially after 
the recent publication of IMPACT study which has added 
new data.
The inhaler combination FF/UMEC/VI has shown a 
good patient adherence and preference from patients, prob-
ably linked to a greater easy handling and ease of use of 
simultaneous administration of three drugs, offering the 
potential for better compliance and results in patients with 
advanced COPD. Obviously, we think that an adequate 
choice of treatment for the patient is fundamental even for 
this combination.
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